What is SS-31?
SS-31, also called elamipretide, is a synthetic peptide studied for its effects on mitochondria, the structures that supply much of a cell's energy. It binds cardiolipin, a fat in the inner mitochondrial membrane. Laboratory work has examined how it interacts with proteins involved in energy production. That explains the interest, but a molecular effect alone cannot tell us whether someone will walk farther, feel less tired or live longer. [1] [2]
There is now a real approved use. In September 2025, the US Food and Drug Administration granted accelerated approval to Forzinity, an elamipretide injection, for certain people with Barth syndrome. The broader research remains mixed, so the useful question is what each trial actually tested. [16]
What exactly is Forzinity approved for?
Forzinity is approved to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. It is given under the skin. The approval was based on improvement in knee extensor strength, an intermediate clinical endpoint, and continued approval may depend on confirmation of clinical benefit. It does not cover general fatigue, athletic recovery or slowing aging. [1] [16]
Barth syndrome is a rare genetic disorder affecting cardiolipin metabolism. In the randomized TAZPOWER study, 12 males aged 12 to 35 received elamipretide and placebo in separate 12-week periods. Neither main outcome, six-minute walking distance or the symptom questionnaire's fatigue score, improved significantly over placebo. Muscle strength also did not show a significant advantage during that randomized phase. [3]
Ten participants then entered an open-label extension, and eight reached 168 weeks. Strength measurements increased during longer treatment. The published follow-up also reported a mean walking-distance increase of about 96 metres from the extension baseline. These are encouraging observations in a serious rare disease, but everyone knew they were receiving treatment and there was no continuing placebo comparison. The study cannot establish how much of the change was caused by the drug. [1] [4]
The FDA accepted the strength finding for accelerated approval. A separate confirmatory study, 4TAZPower, is registered as recruiting, with a planned 48 participants and a placebo-controlled assessment of physical function. It had no posted results when checked for this article. [5] [16]
What happened in the other major trials?
Primary mitochondrial myopathy: MMPOWER-3 randomized 218 people to daily subcutaneous elamipretide or placebo for 24 weeks. It did not meet either main outcome: six-minute walking distance or total fatigue. Those are clear negative results for the overall trial. Findings in genetic subgroups have prompted further study, but do not turn the original trial into a positive result. [6] [15]
Heart failure: an early trial in 36 people with reduced ejection fraction found smaller left-ventricular volumes at the end of a single four-hour intravenous infusion in the highest-dose group. That was a short-term structural signal. In the later PROGRESS-HF trial, 71 people received daily subcutaneous treatment or placebo for 28 days. Neither tested dose significantly improved left-ventricular end-systolic volume or ejection fraction. The early infusion result therefore did not establish a sustained heart-function benefit, and neither study established fewer hospitalizations or longer survival. [7] [8]
Dry age-related macular degeneration: ReCLAIM-2 randomized 176 people with noncentral geographic atrophy to elamipretide or placebo for 48 weeks. It missed both main outcomes: average change in low-light visual acuity and growth of the atrophic area. In a separate analysis, 14.6% on treatment gained at least 10 letters on the low-light vision test, compared with 2.1% on placebo. Some exploratory retinal-imaging measures also favoured elamipretide. These findings used nominal statistical tests and need confirmation; they do not make the trial's main outcomes positive. [9]
Has it been tested in older adults?
Yes. A 2021 randomized trial enrolled 39 adults aged 60 to 85 who were selected for low mitochondrial function in a hand muscle. After a single intravenous infusion, the percentage change in maximum muscle ATP production favoured elamipretide. The absolute-change analysis narrowly missed statistical significance. The difference was no longer evident after seven days, and the prespecified fatigue-resistance test did not show a significant benefit. [10]
This is human evidence of a possible short-lived biological effect, not evidence of longer life or lasting relief from fatigue. A separate registered pilot, SHAPE, plans to study subcutaneous treatment in 30 older adults. Its record lists recruitment but was last updated in December 2025, with an estimated completion date that has since passed. No results were posted at this review, so the listing does not establish its actual current progress or an outcome. [11]
What newer results are still unresolved?
NuPower studied people with mitochondrial disease caused by nuclear DNA mutations. Its registry records 102 participants and completion in December 2024, but no posted results. In May 2026, the sponsor announced a conference presentation describing interest in a POLG1 genetic subgroup. The announcement did not provide numerical trial outcomes. It cannot establish whether the overall trial met its goals. [12] [13]
ReNEW, the phase 3 macular-degeneration study, lists 313 participants and an active, not recruiting status, without posted results. Its results will need to be judged against its own prespecified outcomes. The earlier trial's secondary imaging findings are a reason to run that test, not a preview of success. [9] [14]
What are the safety limits?
Injection-site reactions are common. In the small Barth crossover study, all 12 participants had a local reaction during elamipretide treatment, compared with eight during placebo. The current label also warns of serious allergic reactions that have required emergency treatment. Severe kidney impairment changes the prescribing requirements, and human pregnancy and breastfeeding data are lacking. These are reasons for individual clinical review, not a blanket claim of safety. [1]
The studied routes also matter. A short intravenous experiment does not establish the benefits or risks of prolonged injections under the skin. Forzinity is approved for subcutaneous use, not intravenous use. Nor does its approval establish the identity, sterility or equivalence of another product sold under the SS-31 name. [1] [7] [10]
How should you weigh the evidence?
Reasons for interest
- A defined mitochondrial target with laboratory evidence.
- An approved treatment for a narrowly defined Barth syndrome population.
- Long-term strength observations in Barth syndrome and secondary signals worth testing in other conditions.
Important limits
- The randomized Barth study missed its walking and fatigue outcomes.
- Major myopathy, heart-failure and eye-disease trials missed their main outcomes.
- Older-adult research has not established a lasting energy or longevity benefit.
Questions to ask
- Does the evidence concern my diagnosis and the proposed route?
- What measurable benefit would matter, and when would treatment be reassessed?
- What product is being used, and who handles monitoring and adverse reactions?
For someone seeking help with fatigue, the starting point is identifying its cause with a clinician. A plausible mitochondrial mechanism does not identify the cause of an individual's symptoms. The studies above also include manufacturer funding and involvement, which makes the trial design, comparison group and complete results especially useful when weighing a claim. [3] [6] [10]
Where the evidence sits
Barth syndrome
Accelerated US approval for muscle strength at 30 kg or more. Confirmatory research remains necessary.
Other diseases
Several randomized trials missed primary outcomes despite some early or secondary signals.
Older adults
A small single-infusion trial found a transient ATP signal without a significant fatigue-resistance benefit.
Broader claims
These findings do not establish better recovery, sustained energy or longer life in generally healthy people.
Explore related studies on our Science page.
Questions people ask
Is SS-31 FDA approved?
Elamipretide is approved in the United States as Forzinity to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. This is accelerated approval based on knee extensor strength, with clinical benefit still requiring confirmation. It is not an approval for general fatigue, recovery or longevity. [1] [16]
How could it be approved after negative trial results?
The randomized Barth trial did not improve its main walking and fatigue outcomes over placebo. The FDA decision was based on a later muscle-strength finding during open-label treatment. That finding supports the narrow approved use, while the confirmatory trial must address the remaining uncertainty. Results in other diseases answer separate questions. [1] [3] [5]
Does it improve energy or slow aging?
A small trial in selected older adults found a short-lived signal in muscle ATP production, but no significant benefit on its prespecified fatigue-resistance test. It did not test lifespan or establish a lasting improvement in everyday energy. The mechanism and early result justify further research, not a claim that SS-31 reverses aging. [10]
Is a vial labeled SS-31 the same as Forzinity?
SS-31 and elamipretide name the same molecule, but a name on a vial does not establish that it is the approved product. Forzinity has a specified formulation for subcutaneous use. A clinician and pharmacist need to establish the actual product, source and suitability; trial results do not verify an unrelated vial. [1]
What to take away
- SS-31 and elamipretide refer to the same molecule. Forzinity is a specific approved product.
- The US approval concerns muscle strength in Barth syndrome at a body weight of at least 30 kg.
- The approval is accelerated, and the open-label strength finding still needs confirmation of clinical benefit.
- Results in other diseases are mixed, with several negative primary outcomes.
- The evidence does not establish general anti-aging or sustained energy benefits.
The evidence
Original trial reports, regulatory documents and trial records are linked below. The sponsor announcement is labeled separately. Sources and registry status checked November 9, 2026.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. SS-31 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.